How microsclerotherapy telangiectasis with the creation of procaine infiltration
The invention relates to medicine, in particular to vascular surgery. The method provides a reduction in the frequency and decrease the severity of local urticaria, as well as microtrombidiidae. Carry out the introduction of sclerosant and the compression space sclerosing, in doing so, a subdermal introduction under vascular “asterisks” 5-10 ml of 0.25% solution of novocaine with the creation of procaine infiltration, then the Central vein telangiectasia injected sclerosant to the complete displacement of blood from the capillaries and carry out immediate elastic bandaging overlay foam pads for compression space sclerosing. 2 Il.
The invention relates to medicine, namely to the section of vascular surgery, phlebology, and can be used for the treatment of telangiectasia.
Known methods of preventing local urticaria, epidermal necrosis and the formation of netlanguages due to microsclerotherapy, when immediately after injection of sclerosing drug capillary “spider veins” on teleangiectasia put a layer of hormone ointment [Yablokov E. G., Kiriyenko ago method of treatment are: to apply the ointment after evolved phenomena aseptic inflammation due to sclerosing; small efficiency ointment in conditions of inflammation; the inability to prevent microtrombidiidae (thrombophlebitis capillaries “spider veins”) and hyperpigmentation.
The closest to the technical nature of the claimed invention is selected as a prototype method for the treatment set out in article Bogacheva C. Y., Kiriyenko A. I., Zolotukhin, I. A. Compression sclerotherapy of varicose veins and telangiectasias (experience with the drug, Fibreboard Wayne and techniques microsclerotherapy), Angiology and vascular surgery, 1997, No. 4, S. 27-32. This method is implemented by introducing into the Central vein telangiectasia weak solutions of (0,15-0,25%) of sclerosant with the subsequent elastic compression space sclerosing.
The prototype of the invention has the following similar significant features: the introduction of weak solutions of (0,15-0,2%) of sclerosant into the Central vein telangiectasia followed elastic compression space sclerosing.
The disadvantage of the prototype is a high probability of developing complications, such as microthrombosis, local urticaria, epidermal necrosis, the formation of netlanguages, hyperpigmentation.
The aim of the invention the frequency of microtrombidiidae, netlanguages and hyperpigmentation when microsclerotherapy.
This goal is achieved by introduction directly under the dermis of local anesthetic - novocaine immediately before sclerotherapy of telangiectasias and the creation of procaine infiltration, which, together with the foam cushion from the outside safer squeezes teleangiectases. In addition, novocaine completely eliminates all painful sensations during the procedure.
Implementation of the proposed method subcutaneous injection of novocaine is a distinguishing characteristic in comparison with the prototype and significantly reduces inherent in the prototype above-mentioned disadvantages.
Thus, in relation to the prototype of the claimed invention are distinctive features: other the sequence of execution; the effect on another object; the presence of an additional mechanism of action. While distinguishing between these characteristics and the aim of the invention there is a causal relationship.
According to the authors the information set of essential features that characterize the essence of the claimed invention, is not known from the level of medicine that allows to make a conclusion about conformity of the invention, the criterion of “novelty is medicine, since it is not detected above the impact on the result of the distinctive sign that distinguish the claimed invention from the prototype. This allows to make a conclusion about its compliance with the criterion of “inventive step”.
A distinctive feature of the claimed invention, characterizing its nature, can be reused in phlebology to ensure targets that allows to make a conclusion about conformity of the invention, the criterion of “practical application”.
The invention is illustrated graphic material, which depicts the creation of procaine infiltration when microsclerotherapy.
How microsclerotherapy with the creation of procaine infiltration is implemented as follows. After cleaning the skin with an antiseptic under the vascular asterisk subdermal inject 5-10 ml (depending on the size of the vascular “stars”) of 0.25% solution of novocaine, creating a small infiltrate (Fig.1). Then in the Central vein telangiectasia using an insulin syringe and microneedle 30G injected sclerosant (for example, 0.2% solution of tamboura) to complete displacement of blood from the capillaries. Next, carry out immediate bandaging district put in place the new cushion 13×6 cm for compression space sclerosing (Fig.2) and produce further bandaging. Continuous compression is carried out for 3 days, after which permitted the removal of the bandage at night.
The claimed invention can be used in medicine and in comparison with the prototype has the following advantages:
- significantly reduces the frequency of epidermal necrosis and severity of local urticaria;
- significantly reduces the number of microtrombidiidae, Neotel-angiectases and hyperpigmentation after microsclerotherapy (see table).
How microsclerotherapy telangiectasia, including the introduction of sclerosant and the compression space sclerosing, characterized in that conduct subdermal introduction under vascular “asterisks” 5-10 ml of 0.25% solution of novocaine with the creation of procaine infiltration, then the Central vein telangiectasia injected sclerosant to the complete displacement of blood from the capillaries and carry out immediate elastic bandaging overlay foam pads for compression space sclerosing.
FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.
EFFECT: higher efficiency of therapy.